Please login to the form below

Not currently logged in

Celyad appoints Dr David Gilham as R&D vice president

He will resign from the company’s advisory board to fulfill his new role

Celyad Dr David GilhamBelgian biopharmaceutical company Celyad has selected Dr David Gilham to be its new vice president of research and development.

Currently a member of Celyad's immuno-oncology scientific advisory board, Dr Gilham will resign from his post in August to fulfill his new role from 1 September.

Dr Gilham brings extensive experience in the field of CAR-T cells, with his research activity focused on engineering T-cells for cancer therapies and pre-clinical study development. 

Before joining Celyad Dr Gilham was a Reader in the Institute of Cancer Sciences at the University of Manchester, and led the Manchester Cancer Research Centre's clinical and experimental immunotherapy group.

Dr Gilham said: “I am truly excited to be joining Celyad at such an important time in its history.

“Engineering immune system T-cells to attack and eradicate cancer is at the leading edge of cancer research and I look forward to advancing Celyad's unique portfolio of cell therapy candidates in the clinic.”

16th June 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....
The Periodic Table of Healthcare Communications
The definitive framework for building healthcare communication strategies and plans. Covering Brand Planning, Customer Experience and Multi-channel Marketing....